Iovance Reports Updated IOV-LUN-202 Results and TIL Strategy

Iovance reported a 24.6% objective response rate among 69 patients with non-squamous metastatic non-small-cell lung cancer, consistent with previous results. The company also added a precision TIL strategy for second-line treatment.